Idexx Laboratories (NASDAQ: IDXX)
Key Data Points
Idexx Laboratories Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Idexx Laboratories Company Info
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.
News & Analysis
Meet the Little-Known S&P 500 Stock That Has Rocketed 10,230% Higher Since 2000
Why Idexx Labs Stock Rocketed Higher This Week
Idexx: Q4 EPS, Revenue Beat Forecast
Idexx Laboratories exceeded earnings expectations for Q4 2024, buoyed by robust performance in its key diagnostic segments.
A Once-in-a-Decade Opportunity: 2 Magnificent S&P 500 Stocks Down 37% and 28% to Buy Before 2025
A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback
Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today.
Idexx Sees Q3 Revenue Boost
Idexx Laboratories reported a strong earnings beat for Q3 2024, but adjusted its revenue guidance downward due to ongoing market challenges and litigation costs.
IDEXX: Strong CAG Growth, Mixed Results
IDEXX Laboratories reported mixed earnings, with strong segment gains tempered by some challenges.
3 Nasdaq Stocks That Have Generated 10x Returns in 10 Years
Have these stocks become too expensive to buy today?
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.